Mylan boosted its cash-and-stock offer to buy Perrigoto $34.10 billion, a bid that was swiftly rejected.
Mylan’s pursuit of Perrigo, a major producer of over-the-counter drugs, is widely seen as an attempt to fend off a $40 billion offer from Teva Pharmaceutical Industries the world’s biggest maker of generic drugs.
Mylan’s latest offer comprised $75 in cash and 2.3 of its shares for each Perrigo share, up from its previous offer of $60 in cash and 2.2 of its shares.
Perrigo’s rejection further intensifies a three-way battle to gain abigger share of the generic drugs market as more leading drugs lose patent protection.
“Today’s announcement from Mylan continues to propose a price lower than the previously rejected proposal,” Perrigo said.
Full Content: The New York Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
UK Business Secretary Calls for More Agile Competition Regulator
Feb 13, 2025 by
CPI
Germany’s Antitrust Regulator Raises Concerns Over Apple’s App Tracking Policies
Feb 13, 2025 by
CPI
$60 Billion Nissan-Honda Merger Falls Apart
Feb 13, 2025 by
CPI
DOJ Moves to End Protections for Three Regulatory Agencies
Feb 13, 2025 by
CPI
Meta to Allow Rivals to List Ads on Facebook Marketplace Following EU Fine
Feb 13, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – International Criminal Enforcement
Jan 23, 2025 by
CPI
The Antitrust Division’s Recent Work to Combat International Cartels
Jan 23, 2025 by
Emma Burnham & Benjamin Christenson
Information Sharing: The New Frontier of U.S. Antitrust Enforcement
Jan 23, 2025 by
Brian P. Quinn, Casey Kovarik & Michael Tubach
The Key Role of Guidelines on Exchanges of Information Among Competitors and the Divergent Transatlantic Paths
Jan 23, 2025 by
Rosa Abrantes-Metz & Albert Metz
Leniency, Whistleblowers, and Compliance
Jan 23, 2025 by
Richard Powers, Tara O’Malley & Cory Gordon